Rigel Pharmaceuticals (RIGL) late Tuesday reported a Q4 net income of $13.54 per diluted share, up from $0.80 a year earlier.

Analysts polled by FactSet expected $1.20.

Revenue for the quarter ended Dec. 31 rose to $69.8 million from $57.6 million a year earlier.

Analysts surveyed by FactSet expected $68.7 million.

For 2026 the company expects total revenues of $275 to $290 million. Analysts polled by FactSet expect $279.3 million.